Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
161
resultados
Última actualización
06/06/2025 [06:58:00]
Resumen de: US2025182875A1
An apparatus comprising a controller. The controller includes an input/output (I/O) module and a rule module. The I/O module is configured to present a question for a patient when communicatively coupled to a user interface and receive patient information in response to the question via the user interface. The rule module is configured to apply a rule to the patient information and generate a suggested insulin pump setting from application of the rule. Other devices, systems, and methods are disclosed.
Resumen de: US2025180505A1
A glucose biosensor encasement includes a first membrane and a second membrane. The first membrane has a first interlocking segment. The second membrane has a second interlocking segment cooperating with the first interlocking segment of the first membrane to provide a cavity between the first membrane and the second membrane configured to receive a glucose sensor. At least one of the first membrane and the second membrane comprises a semi-permeable portion configured to regulate diffusion characteristics of glucose through the membrane to realize a sensitivity for a sensor in the cavity. A method is also provided.
Resumen de: AU2025203519A1
The present disclosure is directed to a composite implant for the sustained release of a therapeutic agent from a hydrogel matrix. The hydrogel matrix may be a cross-linked bioerodible polyethylene glycol (PEG) hydrogel with a therapeutic complex dispersed within the cross-linked bioerodible PEG hydrogel. The therapeutic complex may include a therapeutic agent in association with mesoporous silica particles. The composite implant is configured to be delivered to or implanted into an eye of a subject or patient. The composite implant may be used treat ocular disease in a subject or patient. Ocular diseases may be selected from at least one of neovascular age related macular degeneration (AMD), diabetic macular edema, or macular edema following retinal vein occlusion.
Resumen de: US2025182874A1
An insulin delivery supervisor (IDS) with a safety analysis and supervision function that can reside between the insulin request and the insulin delivery and can intercept any excessive insulin requests before the insulin was delivered. The IDS can be implemented in any system based on insulin pump or pen and will work with either SMBG or CGM modes of blood glucose monitoring.
Resumen de: US2025180540A1
A blood glucose measurement device having a display, includes a housing having one or more openings on one side, one or more contact electrodes configured to electrically coupled to a sensor strip inserted into the housing through the one or more openings, one or more control buttons configured to turn on the blood glucose measurement device, and one or more processors configured to control a first execution screen to be displayed in response to receiving a first signal by the one or more contact electrodes and, display a second execution screen in response to receiving a second signal by the one or more control buttons.
Resumen de: AU2023312740A1
Systems, devices and methods are provided for incorporating a medication delivery device into an integrated management system. The integrated management system may be an integrated diabetes management system and may include a glucose monitor, a connected insulin pen, and software. The integrated management system may produce a plurality of reports that may include data related to analyte levels (e.g., glucose levels) and medication delivered (e.g., insulin delivered). The medication delivery device may also provide feedback to the user.
Resumen de: WO2025109398A1
Non-enzymatic electrochemical glucose sensor (100), for the detection of glucose in biological fluids, characterized in comprising: - a support (101), having a first surface and a second surface opposite to the first surface; - a first metallic electrode (102a), a second metallic electrode (102b), and a third metallic electrode (102c) deposited on said support (101); - a sensitive element consisting of a compound, having a nanoporous structure, deposited on a surface of the second metallic electrode (102b). The invention is also related to a fabrication process of the non-enzymatic electrochemical glucose sensor (100).
Resumen de: US2025172539A1
Techniques for data processing and control for a glucose monitoring system are provided, including obtaining a first sensitivity of a glucose sensor; obtaining a second sensitivity of the glucose sensor; comparing a difference between the first sensitivity and the second sensitivity to a predetermined range of values; if the difference is outside the predetermined range of the values, causing a calibration routine for the glucose sensor to be performed; and if the difference is within the predetermined range of values determining a composite sensitivity for a current calibration of the glucose sensor based on the first sensitivity and the second sensitivity and calculating the glucose level based on the current calibration of the glucose sensor.
Resumen de: AU2025203318A1
Systems, devices, and methods are disclosed for wireless communication of analyte data. In embodiments, a method of using a diabetes management partner interface to configure an analyte sensor system for wireless communication with a plurality of partner devices is provided. The method includes the analyte sensor system receiving authorization to provide one of the partner devices with access to a set of configuration parameters via the diabetes management partner interface. The set of configuration parameters is stored in a memory of the analyte sensor system. The method also includes, responsive to input received from the one partner device via the diabetes management partner interface, the analyte sensor system setting or causing a modification to the set of configuration parameters, according to a system requirement of the one partner device.
Resumen de: AU2025203317A1
Systems, devices, and methods are disclosed for wireless communication of analyte data. One such method includes, during a first interval, establishing a first connection between an analyte sensor system and a display device. During the first connection, the method includes exchanging information related to authentication between the analyte sensor system and the display device. The method includes making a determination regarding whether authentication was performed during the first interval. During a second interval, the method may include establishing a second connection between the analyte sensor system and the display device for transmission of an encrypted analyte value, and bypassing the exchanging of information related to authentication performed during the first connection. The method also includes, during the second interval, the analyte sensor system transmitting the encrypted analyte value to the display device, if the determination indicates that the authentication was performed during the first interval.
Resumen de: AU2025203433A1
Personalized treatment tool Abstract The present invention relates to a computer-implemented method for aiding in the guidance of diabetes drug therapy of an individual suffering from diabetes mellitus. The method is based on glucose data from said individual that are received at a processing unit, wherein said glucose data comprise at least three fasting glucose measurement values from said in 10 dividual, and/or at least three matched pre-prandial glucose measurement values and post prandial glucose measurement values at the same meal from said individual. Further con templated by the present invention is a device for aiding in the guidance of drug diabetes therapy of an individual suffering from diabetes, said device comprising a processing unit, and a computer program including computer-executable instructions, wherein said instruc 15 tions, when executed by the processing unit, causes the processing unit to perform the com puter-implemented method of the present invention.
Resumen de: US2025170330A1
Disclosed herein are systems and methods for closed loop and/or partial and/or hybrid closed loop therapy that can provide adaptive personal profiles for when glucose levels are not available and/or unreliable from a continuous glucose monitor (CGM), such as, for example, during a warmup period of the CGM sensor. The profile can include temporary delivery profile such as a CGM warmup profile that is activated specifically for the particular scenario and is designed to minimize the risk of blood glucose fluctuations until the glucose levels are available and reliable, such as when the CGM sensor is warmup up and closed loop therapy based on the sensor can be activated.
Resumen de: US2025172566A1
The present invention relates to saccharide sensing systems including macrocyclic compounds which are capable of binding to a target saccharide (e.g. glucose) and a detectable reporter for providing a detectable signal based on the binding of the target saccharide by the macrocyclic compound.
Resumen de: US2025169721A1
A notification device is provided for presenting blood glucose level information for a tracked individual. The notification device is configured to receive first and second blood glucose level information from first and second tracking devices associated with different manufacturers. The first and second blood glucose level information each include at least one of a blood glucose level or a first or second derivative for the blood glucose level as a function of time. The notification device comprises a screen, processor(s), and memory device(s) containing computer readable code. When executed by the processor(s), the computer readable code is configured to cause the processor(s) to receive the first and/or the second blood glucose level information and cause presentation of the first and/or the second blood glucose level information on the screen. The first and second tracking devices are each a continuous blood glucose monitor.
Resumen de: US2025169720A1
A biological test system has receptacles for a variety of removable electro-mechanical biological blood test-based elements having multiple features such as lancets or strips. Testing is through an analysis biological test processor that provides results to a user test output with all designed to be contained in a pocket-transportable user biological test form factor that houses all elements. Biological test elements can be interchanged for multiple sensing modalities with automatic activation based on cartridge insertion of a glucose test element, an A1C test element, a ketone test element, or the like. Designs can include a user sampler configuration selector for a user sampling selection that may be analyzed so a user-personalizable, biological sampler control processor can automatically disable operation for test safety if a user sampling selection is determined to be unacceptable. The system can also provide a user cartridge action prompt, a user reselection prompt, or other action to clear the disable.
Resumen de: US2025169728A1
The present disclosure describes lactate-responsive sensors, sensing systems incorporating a lactate-responsive sensor, and methods of use thereof that would be beneficial for continuously monitoring lactate levels and determining lactate thresholds (both aerobic and anaerobic thresholds). The present disclosure also relates to an analyte sensor for continuously detecting glucose and lactate levels.
Resumen de: US2025169769A1
A continuous analyte monitoring system includes first and second analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller Is coupled to the analyte sensors and configured evaluate first samples of outputs of the first analyte sensor and second samples of outputs of the second analyte sensor with respect to one another to determine whether the first samples and the second samples indicate compression of the tissue. If the first samples and the second samples indicate compression of the tissue, compensate for the compression of the tissue with respect to the first samples. The controller may evaluate the machine learning models using a machine learning model or a filter.
Resumen de: US2025174328A1
A system for prescribing insulin doses is provided, wherein a first titration application component structured to is implemented on a patient computing device of the patient, wherein the first titration application component logs glucose level data measured from the patient and insulin dose data indicative of a number of insulin doses given to the patient. The system includes a provider computing including a second titration application component, wherein the second titration application component is structured and configured to receive the glucose level data and the insulin dose data from the patient computing device, determine a correction factor based on a sensitivity constant specified by the healthcare provider, and determine the insulin dose recommendation for the patient based on the insulin dose data, the glucose level data and the correction factor, wherein the provider computing device is structured and configured to transmit the insulin dose recommendation to the patient computing device.
Resumen de: US2025169764A1
Continuous Glucose Monitoring (CGM) devices provide glucose concentration measurements in the subcutaneous tissue with limited accuracy and precision. Therefore, CGM readings cannot be incorporated in a straightforward manner in outcome metrics of clinical trials e.g. aimed to assess new glycemic-regulation therapies. To define those outcome metrics, frequent Blood Glucose (BG) reference measurements are still needed, with consequent relevant difficulties in outpatient settings. Here we propose a “retrofitting” algorithm that produces a quasi continuous time BG profile by simultaneously exploiting the high accuracy of available BG references (possibly very sparsely collected) and the high temporal resolution of CGM data (usually noisy and affected by significant bias). The inputs of the algorithm are: a CGM time series; some reference BG measurements; a model of blood to interstitial glucose kinetics; and a model of the deterioration in time of sensor accuracy, together with (if available) a priori information (e.g. probabilistic distribution) on the parameters of the model. The algorithm first checks for the presence of possible artifacts or outliers on both CGM datastream and BG references, and then rescales the CGM time series by exploiting a retrospective calibration approach based on a regularized deconvolution method subject to the constraint of returning a profile laying within the confidence interval of the reference BG measurements. As output, the retrofitting al
Resumen de: WO2025106990A1
Integrated patch-pump devices to deliver drugs, e.g., macromolecular drugs that are difficult to deliver through an oral pathway and/or that require transdermal delivery. Embodiments are slim, powerless, painless, and relatively inexpensive. The microfluidic pump is used to drive the fluid flow powered by pressurized air or the user's pulse, and the microneedle array is used to inject the fluid through the skin painlessly. The flow rate generally positively correlates with the actuation pressure. For devices with wider flow channels, the flow rate generally negatively correlates with the actuation frequency, whereas the flow rate increases and then decreases with increasing actuation frequency for devices with narrower flow channels. This property of these devices is beneficial in insulin delivery because the demand for insulin is generally reduced in vigorous exercise (with elevated heart rate/ actuation frequency) and is increased in hypertension patients (with elevated blood/actuation pressure).
Resumen de: WO2025106280A1
Techniques are provided for dynamically managing wireless communications of glucose monitoring systems. The systems dynamically adjust the communication session intervals based on various dynamic conditions. Some systems are also configured with an antenna positioned on an opposing side of a chip from other sensor electronics and/or outside of an encasing of potting material to enhance the signaling functionality of the antenna.
Resumen de: WO2025102900A1
A non-invasive blood glucose measurement system (100), comprising an optical transceiver assembly (110); a filtering unit (120), electrically connected to the optical transceiver assembly (110); and a micro-processing unit (130), electrically connected to the filtering unit (120). The optical transceiver assembly (110) comprises: at least two light sources (111), a first detector (112) and at least two second detectors (113), the at least two light sources (111) being used for emitting laser detection signals, and the first detector (112) and the at least two second detectors (113) being used for detecting returned laser signals. The at least two light sources (111) are provided around the first detector (112); the at least two second detectors (113) are provided around the light source (111); and a light detection surface of the first detector (112), light detection surfaces of the at least two second detectors (113), and light emergent surfaces of the at least two light sources (111) face the same direction. Data analysis and processing of short-path optical signals and long-path optical signals can obtain an optical concentration difference between a dark portion and a light portion of skin, thereby reducing the influences caused by melanin and skin, and improving the accuracy in non-invasive blood glucose measurement.
Resumen de: WO2025102532A1
Provided is an insulin pen needle rear end protection device, which comprises: a housing (1), wherein the tail end of the housing (1) is arranged to be connected with an insulin injection pen; a needle holder (2) fixed in the housing (1), wherein an injection needle extending to the tail end of the housing (1) is arranged on the needle holder (2), a guide groove (22) is formed in the side wall of the needle holder (2), and a protruding block (23) is further arranged on the inner surface of the side wall of the needle holder (2); and a rear needle protective sleeve (3) arranged in the needle holder (2) in a penetrating manner, wherein a spring (4) is clamped between the rear needle protective sleeve (3) and the needle holder (2), and a positioning column (31) and an elastic clamping jaw (32) are arranged on the outer surface of the rear needle protective sleeve (3). When the insulin pen needle is connected to the injection pen, the rear needle protective sleeve (3) is compressed into the needle holder (2), the positioning column (31) moves in the guide groove (22) to a first position, and the elastic clamping jaw (32) is located on the side of the protruding block (23) away from the tail end of the needle holder (2); when the insulin pen needle is separated from the injection pen, the positioning column (31) moves to a second position along the guide groove (22) under the acting force of the spring (4), such that the rear needle protective sleeve (3) pops up, and the elastic c
Resumen de: WO2025102533A1
An insulin pen needle front-end protection apparatus, comprising a housing (1), the housing(1) being provided with a first through hole (11) in a head end; a needle base (2) fixedly connected to a tail end of the housing (1), the needle base (2) being provided with a protruding portion (21) extending towards the head end of the housing (1), and an injection needle (22) extending out of the first through hole (11) being arranged on the protruding portion (21); a sliding buckle (3) sleeved on the protruding portion (21), a constriction structure being arranged at a tail end of the sliding buckle (3), and a head end of the sliding buckle (3) being provided with a second through hole (31); and a needle tip protection sleeve (4) at least partially arranged in the housing (1), a spring (5) being clamped between a tail end of the needle tip protection sleeve (4) and the needle base (2), a head end of the needle tip protection sleeve (4) extending out of the first through hole (11) and being provided with a third through hole (41), and at least two clamping buckles (42) being arranged on an inner wall of the needle tip protection sleeve (4).
Nº publicación: WO2025102531A1 22/05/2025
Solicitante:
WTTOD US INC [US]
LU JUN [CN]
\u536B\u56FE\u5FB7\u7F8E\u56FD\u6709\u9650\u516C\u53F8,
\u9646\u519B
Resumen de: WO2025102531A1
A protection device for the front end of an insulin pen needle, comprising: a housing (1); a needle hub (2), which is fixed in the housing (1), the needle hub (2) being provided with an injection needle extending out of the head end of the housing (1); a sliding fastener (3), which is sleeved on the needle hub (2) and is in sliding fit with the needle hub (2), the outer surface of the sliding fastener (3) being provided with a snap-fit portion (31); and a needle tip protective sleeve (4), which is slidably provided in the housing (1), an elastic piece (41) being provided on single side of the inner wall of the needle tip protective sleeve (4), and a spring (5) is clamped between the needle tip protective sleeve (4) and the needle hub (2). When the insulin pen needle is in an injection state, the needle tip protective sleeve (4) presses the spring (5) to retract into the housing (1), such that the needle tip protective sleeve (4) is sleeved on the sliding fastener (3), and in the case that the elastic piece (41) slides to the position of the snap-fit portion (31), the elastic piece (41) hooks the snap-fit portion (31), so as to expose the needle tip of the injection needle (21). When the insulin pen needle is in a retraction state, the needle tip protective sleeve (4) extends out of the housing (1) under the elastic force of the spring (5) and drives the sliding fastener (3) to withdraw from the needle hub (2); the sliding fastener (3) is offset with the needle hub (2) under t
BOPI
Sede Electrónica
